Cell-free DNA as a prognostic biomarker in patients with COVID-19 disease

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00031641

Enrollment

Registered

2023-07-13

Start date

2023-07-17

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cfDNA in patients with COVID-19

Interventions

Group 1: Biobank material from SARS-CoV-2 positive patients will be analysed for cfDNA levels and correlated with clinical outcome parameters. Group 2: Prospectively collected cfDNA measurements from

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: COVID-19 disease

Exclusion criteria

Exclusion criteria: - pregnancy - breast feeding women - Blood sample taken too late - medication (Remicade, Tofacitinib)

Design outcomes

Primary

Measure	Time frame
Correlation of cfDNA with disease severity during its course, as measured by the WHO clinical progression scale.	—

Secondary

Measure	Time frame
- Mortality -pre-existing conditions -organ replacement procedures (ECMO, ventilation, dialysis, catecholamines) - standard laboratory parameters (CRP, PCT, D-dimer, LDH, ...) - duration of hospital stay - duration of ICU stay	—

Countries

Germany

Contacts

Public ContactKatharina Hoeter

Universitätsmedizin Mainz der Johannes Gutenberg-Universität Mainz

katharina.hoeter@unimedizin-mainz.de017663151835

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026